The Phase 3 study examined Exparel as a single-dose femoral nerve block in the adductor canal for postsurgical regional analgesia in total knee replacement patients, according to a Sept. 7 news release from the company. The study demonstrated a “statistically significant” reduction in pain scores and opioid consumption through 96 hours after surgery.
Pacira plans to submit a new drug application to the FDA and will seek expansion of the Exparel label to include femoral nerve block in the adductor canal.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.